Bone Mineral Density and Vitamin D Status in Nigerians: The Impact of HIV.
Abene EE, Gimba ZM, Rawizza H, Odoh G, Amusa GA, Chundusu DY, Imoh LC, Agaba EI, Sagay SA.
West Afr J Med. 2023 04 28. 40(4):414-420. PMID: 37120756
Links
Bibliography
Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.
Chaplin B, Agbaji O, Reyes Nieva H, Olatunde B, Chang C, Mitruka K, Sule H, Dajel T, Zee A, Ahmed ML, Ahmed I, Okonkwo P, Rawizza H, Kanki P.
Clin Infect Dis. 2023 02 08. 76(3):e671-e680. PMID: 35872644
Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
Rawizza HE, Oladokun R, Ejeliogu E, Oguche S, Ogunbosi BO, Agbaji O, Odaibo G, Imade G, Olaleye D, Wiesner L, Darin KM, Okonkwo P, Kanki PJ, Scarsi KK, McIlleron HM.
J Antimicrob Chemother. 2021 02 11. 76(3):710-717. PMID: 33294914
Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread.
Nazziwa J, Faria NR, Chaplin B, Rawizza H, Kanki P, Dakum P, Abimiku A, Charurat M, Ndembi N, Esbjörnsson J.
Sci Rep. 2020 02 26. 10(1):3468. PMID: 32103028
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Rawizza HE, Darin KM, Oladokun R, Brown B, Ogunbosi B, David N, Akanmu S, Olaitan O, Chang C, Scarsi KK, Okonkwo P, Kanki PJ.
J Antimicrob Chemother. 2019 09 01. 74(9):2707-2715. PMID: 31139825
Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
Rabie H, Rawizza H, Zuidewind P, Winckler J, Zar H, Van Rie A, Wiesner L, McIlleron H.
J Antimicrob Chemother. 2019 08 01. 74(8):2347-2351. PMID: 31081020
INCIDENCE OF ANAEMIA AMONG HIV-INFECTED PATIENTS TREATED WITH ZIDOVUDINE-CONTAINING ANTIRETROVIRAL THERAPY IN NORTHEASTERN NIGERIA.
Ikunaiye NY, Denue BA, Aina BA, Aderemi-Williams R, Rawizza HE.
Ann Ib Postgrad Med. 2018 Dec. 16(2):115-124. PMID: 31217768
Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
Chaplin B, Imade G, Onwuamah C, Odaibo G, Audu R, Okpokwu J, Olaleye D, Meloni S, Rawizza H, Muazu M, Musa AZ, Samuel J, Agbaji O, Ezechi O, Idigbe E, Kanki PJ.
AIDS Res Hum Retroviruses. 2018 02. 34(2):228-233. PMID: 29084434
Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options.
Meloni ST, Onwuamah CK, Agbaji O, Chaplin B, Olaleye DO, Audu R, Samuels J, Ezechi O, Imade G, Musa AZ, Odaibo G, Okpokwu J, Rawizza H, Mu'azu MA, Dalhatu I, Ahmed M, Okonkwo P, Raizes E, Ujah IAO, Yang C, Idigbe EO, Kanki PJ.
Open Forum Infect Dis. 2017. 4(4):ofx233. PMID: 29255731
On the Cusp.
Knelson EH, Vaidya A, Rawizza HE, Vaduganathan M, O'Gara PT.
N Engl J Med. 2017 05 25. 376(21):e45. PMID: 28538122